Oxidative Stress and Inflammation in Renal Patients and Healthy Subjects

Lee, Diana M.; Jackson, Kenneth W.; Knowlton, Nicholas; Wages, J. A.; Alaupovic, Petar; Samuelsson, Ola; Saeed, Aso; Centola, Michael; Attman, Per‐Ola

doi:10.1371/journal.pone.0022360

Cited by 24 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of the presented studies and those by of other laboratories have already shown that TG-rich apoB-containing apoCIII lipoproteins are linked to inflammation [1,2,[12][13][14], and that oxidation is not always proatherogenic [7,15]. Moderate oxidation that encompasses in vivo conditions destabilizes VLDL and promotes the fission of HDL-size particles.…”

Section: Discussionsupporting

confidence: 54%

Moderate dyslipoproteinemia induced inflammation and remodeling HDL and VLDL particles in post-renal transplant patients

Kimak

Baranowicz-Gąszczyk

Białopiotrowicz

2017

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

oxidation of low density lipoprotein (LDL). These include apolipoprotein AI (apoAI), lecithin: cholesterol acyltransferase (LCAT), and paraoxonase-1 (PON1) [8,9]. However, the proteins interaction in the anti-oxidant activity of HDL is unknown. ApoAII has been shown to directly affect HDL modifications catalyzed by the plasma proteins. ApoAII is less efficient than apoAI at activating LCAT [10,20], and studies have shown that displacement of apoAI in HDL by apoAII inhibits cholesterol esterification. A possible mechanism of the pro-atherogenic action of human apoAII could be the inhibition of reverse cholesterol transport (RCT), depending, at least partly on a marked disease in endogenous The aim of this paper was to examine whether moderate dyslipoproteinemia can cause an increase of hsCRP and LPO levels in Tx patients who had received immunosuppressive therapy and were without acute inflammatory diseases. Herein, the lipid levels, hsCRP, LPO, apolipoprotein (apo)B, AI, AII, AIInonB, apoB-containing AII (apoB:AII), apoCIII, apoCIIInonB, apoB:CIII, LCAT level, as well as CETP and PON1 activity were determined. All examined Tx patients had moderate dyslipidemia and slightly increased hsCRP, LPO, apoB:AII and apoCIII levels, but decreased LCAT mass, PON1 activity and lipoprotein ratios. Tx patients with apoAI<150 mg/dl (n=28) had worse lipoprotein profiles than did Tx patients with apoAI>150mg/dl (n=39), but no difference in CETP activity was indicated. Multiple ridge forward regression and Spearman's correlation test were used. The results of the presented study, show for the first time that higher apoAI/apoB and apoAI/apoCIII ratios induced a decrease of the hsCRP concentration. Moreover, the composition of apoCIIInonB, LDL-C and apoAI brought about an increase of LCAT mass and PON1 activity. In Tx patients with lower concentration of apoAI, an increase of concentration of apoB:AII in VLDL generated a mild oxidation of lipoprotein and an elevated concentration of LPO. However, lower ApoAI/apoB ratio resulted in an increase of PON1 activity and apoB, as well as nonHDL-C levels, and in turn, PON1 activity increased LCAT mass. These disorders rearranged the HDL particle, and, simultaneously, remodeled the VLDL particle. This may prevent antioxidant activity, reverse cholesterol transport and accelerate the rejection of the transplant, as well as bringing about cardiovascular diseases in Tx patients with lower apoAI. Such metabolic pathways can be used as potentially novel targets for pharmacological intervention.

show abstract

Section: Discussionsupporting

confidence: 54%

Moderate dyslipoproteinemia induced inflammation and remodeling HDL and VLDL particles in post-renal transplant patients

Kimak

Baranowicz-Gąszczyk

Białopiotrowicz

2017

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Whereas some reported deceased levels of AGEs when HDF was applied [39,41], others demonstrated no effect [34]. Until now, the effect of HDF on novel inflammatory biomarkers like PTX3, TG48 [48], TWEAK [49] or TRAIL [50] waits for further studies.…”

Section: Effects Of Hdf On Uremic Inflammationmentioning

confidence: 99%

Effects of Hemodiafiltration on Uremic Inflammation

2013

View full text Add to dashboard Cite

Chronic inflammation is highly prevalent among end-stage renal disease patients and is linked to, and thought to contribute to, the high morbidity and mortality in this patient population. Hemodiafiltration (HDF) may potentially reduce inflammatory stimuli induced by the bioincompatibility of conventional hemodialysis (HD) systems. In addition, HDF may more efficiently remove inflammatory mediators. This brief review shows that the circulating levels of various markers of systemic inflammation in general are somewhat reduced in patients treated by HDF as compared to HD. On the other hand, according to the current literature, this favorable small impact on inflammation biomarkers does not seem to translate into better clinical outcomes. It is possible that this is due to inadequate design, inadequate number of investigated patients and too short duration of previous studies. The results of larger, better-designed ongoing prospective studies may hopefully clarify this.

show abstract

“…Dialysis CKD patients are reportedly characterized by higher levels of oxidative and inflammation than healthy subjects (11,32–34). Oxidative stress and inflammation are correlated strongly with tryglycerides, VLDL‐C, apoC‐III and apoC‐III bound to apoB‐containing lipoproteins, but not with either TC or LDL‐C (35).…”

Section: Mechanisms Involved In the Therapeutic Effects Of Ldl Apherementioning

confidence: 99%

Therapeutic Potential of Low‐Density Lipoprotein Apheresis in the Management of Peripheral Artery Disease in Patients With Chronic Kidney Disease

et al. 2012

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD). Patients with CKD are reported to have a significant greater risk of CVD-associated mortality than that of the general population after stratification for age, gender, race, and the presence or absence of diabetes. CKD itself is also an independent risk factor for the development of atherosclerosis, and in particular, patients undergoing dialysis typically bear many of the risk factors for atherosclerosis, such as hypertension, dyslipidemia and disturbed calcium-phosphate metabolism, and commonly suffer from severe atherosclerosis, including peripheral arterial disease (PAD). Low-density lipoprotein (LDL) apheresis is a potentially valuable treatment applied to conventional therapy-resistant hypercholesterolemic patients with coronary artery disease and PAD. Although previous and recent studies have suggested that LDL apheresis exerts beneficial effects on the peripheral circulation in dialysis patients suffering from PAD, probably through a reduction of not only serum lipids but also of inflammatory or coagulatory factors and oxidative stress, the precise molecular mechanisms underlying the long-term effects of LDL apheresis on the improvement of the peripheral circulation remains unclear and warrants further investigation.

show abstract

Oxidative Stress and Inflammation in Renal Patients and Healthy Subjects

Cited by 24 publications

References 38 publications

Moderate dyslipoproteinemia induced inflammation and remodeling HDL and VLDL particles in post-renal transplant patients

Moderate dyslipoproteinemia induced inflammation and remodeling HDL and VLDL particles in post-renal transplant patients

Effects of Hemodiafiltration on Uremic Inflammation

Therapeutic Potential of Low‐Density Lipoprotein Apheresis in the Management of Peripheral Artery Disease in Patients With Chronic Kidney Disease

Contact Info

Product

Resources

About